Trump’s May 2026 decision to replace FDA Commissioner Marty Makary with acting head Kyle Diamantas, a deputy commissioner for food and former corporate attorney with ties to the administration, has anchored trader focus on internal FDA leadership transitions and Senate confirmation dynamics. Multiple candidates including former commissioners Stephen Hahn and Brett Giroir, along with current officials Sara Brenner and Grace Graham, remain under active consideration for the permanent post, yet no formal nomination has advanced amid reported preferences for an M.D. or Ph.D. credential and specific policy alignments. The elevated probability assigned to no announcement by year-end reflects the typical timeline for White House vetting, HELP Committee review, and full Senate action, especially with midterms approaching and acting authority extendable under federal vacancies rules. This positioning underscores the competitive field and procedural hurdles that could shift only with a confirmed nomination or major personnel signal.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日No announcement by December 31 37.0%
Kyle Diamantas 33%
Brett Giroir 10.0%
Stephen Hahn 6%
$11,542 Vol.
$11,542 Vol.
2026/12/31
Kyle Diamantas
33%
Stephen Hahn
6%
Brett Giroir
16%
Grace Graham
5%
Sara Brenner
17%
No announcement by December 31
37%
No announcement by December 31 37.0%
Kyle Diamantas 33%
Brett Giroir 10.0%
Stephen Hahn 6%
$11,542 Vol.
$11,542 Vol.
2026/12/31
Kyle Diamantas
$1,866 Vol.
33%
Stephen Hahn
$1,482 Vol.
6%
Brett Giroir
$2,265 Vol.
16%
Grace Graham
$3,407 Vol.
5%
Sara Brenner
$1,992 Vol.
17%
No announcement by December 31
$550 Vol.
37%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Trump’s May 2026 decision to replace FDA Commissioner Marty Makary with acting head Kyle Diamantas, a deputy commissioner for food and former corporate attorney with ties to the administration, has anchored trader focus on internal FDA leadership transitions and Senate confirmation dynamics. Multiple candidates including former commissioners Stephen Hahn and Brett Giroir, along with current officials Sara Brenner and Grace Graham, remain under active consideration for the permanent post, yet no formal nomination has advanced amid reported preferences for an M.D. or Ph.D. credential and specific policy alignments. The elevated probability assigned to no announcement by year-end reflects the typical timeline for White House vetting, HELP Committee review, and full Senate action, especially with midterms approaching and acting authority extendable under federal vacancies rules. This positioning underscores the competitive field and procedural hurdles that could shift only with a confirmed nomination or major personnel signal.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
マーケット開始日： May 12, 2026, 7:59 PM ET
音量
$11,542終了日
2026/12/31マーケット開始日
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Trump’s May 2026 decision to replace FDA Commissioner Marty Makary with acting head Kyle Diamantas, a deputy commissioner for food and former corporate attorney with ties to the administration, has anchored trader focus on internal FDA leadership transitions and Senate confirmation dynamics. Multiple candidates including former commissioners Stephen Hahn and Brett Giroir, along with current officials Sara Brenner and Grace Graham, remain under active consideration for the permanent post, yet no formal nomination has advanced amid reported preferences for an M.D. or Ph.D. credential and specific policy alignments. The elevated probability assigned to no announcement by year-end reflects the typical timeline for White House vetting, HELP Committee review, and full Senate action, especially with midterms approaching and acting authority extendable under federal vacancies rules. This positioning underscores the competitive field and procedural hurdles that could shift only with a confirmed nomination or major personnel signal.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
音量
$11,542終了日
2026/12/31マーケット開始日
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Trump’s May 2026 decision to replace FDA Commissioner Marty Makary with acting head Kyle Diamantas, a deputy commissioner for food and former corporate attorney with ties to the administration, has anchored trader focus on internal FDA leadership transitions and Senate confirmation dynamics. Multiple candidates including former commissioners Stephen Hahn and Brett Giroir, along with current officials Sara Brenner and Grace Graham, remain under active consideration for the permanent post, yet no formal nomination has advanced amid reported preferences for an M.D. or Ph.D. credential and specific policy alignments. The elevated probability assigned to no announcement by year-end reflects the typical timeline for White House vetting, HELP Committee review, and full Senate action, especially with midterms approaching and acting authority extendable under federal vacancies rules. This positioning underscores the competitive field and procedural hurdles that could shift only with a confirmed nomination or major personnel signal.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問